The role of immunomodulatory medications in the treatment of COVID-19

Sebastian E. Sattui, Mary K. Crow, and Iris Navarro-Millán

Purpose of review
Given the role of inflammation in severe forms of COVID-19, glucocorticoids and disease-modifying antirheumatic drugs (DMARDs) have been assessed as potential COVID-19 therapies.

Recent findings
Randomized controlled trials (RCTs) have shown that glucocorticoids reduce mortality in severe COVID-19. RCTs of DMARDs have shown mixed results varying on intervention and inclusion criteria. DMARDs, including colchicine or biologic agents, may improve COVID-19 outcomes in specific patient populations.

Summary
Glucocorticoids are an effective treatment for the management of severe COVID-19. Further studies are needed to better define the patient populations who could benefit from DMARD use, as well as provide guidance regarding the timing of these interventions.

Keywords
COVID-19, disease-modifying antirheumatic drugs, glucocorticoids, hyperinflammatory

INTRODUCTION
The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory coronavirus (SARS-CoV-2), has led to an unprecedented global health crisis with over 170 million confirmed cases and over 3.7 million deaths as of June 2021 [1]. The severe forms of COVID-19, a hyperinflammatory syndrome characterized by lymphopenia and elevated transaminases, lactate dehydrogenase (LDH), ferritin, D-dimers, as well as elevated inflammatory markers such as C-reactive protein (CRP), interleukin-6 (IL-6), tumor-necrosis factor (TNF)-α and IL-8 have been described [2,3,4]. Some of these features have been identified as poor prognostic factors in patients with COVID-19, independent of other well-established risk factors such as older age, male sex, obesity, and increased comorbidity burden.

Given the resemblance to other hyperinflammatory conditions such as macrophage activation syndrome (MAS), also known as secondary hemophagocytic lymphohistiocytosis (HLH), or chimeric antigen receptor (CAR) T-cell induced cytokine release syndrome (CRS), several immunosuppressive therapies have been and are currently being investigated for the treatment of severe COVID-19. The aim of this review is to summarize data, primarily from randomized clinical trials, regarding the use of immunosuppressive treatments, including glucocorticoids, and disease-modifying antirheumatic drugs (DMARDs) for the treatment of COVID-19 up to May 30th, 2021.

RATIONALES FOR USE OF IMMUNOMODULATORS IN COVID-19
Infection of cells expressing angiotensin-converting enzyme 2 receptors by SARS-CoV-2 represents the initial phase of the disease [5]. The later stage, which is characterized by increased production of proinflammatory cytokines and chemokines such as IL-1, IL-6, TNF-α, and IL-8, mediates organ damage and failure leading to death in severe COVID-19 [6,7]. It is important to note that this two-phase approach is simplistic and that these processes occur concomitantly, resulting in infection of endothelial cells,
both micro- and macrovascular thrombosis, tissue hypoxia, and cellular death [8].

Although DMARDs are predicted to minimize the hyperinflammation, Janus kinase (JAK) inhibitors could additionally have a role in the inhibition of viral entry by blocking AP2-associated protein kinase 1 (AAK1), a regulator of the endocytosis [9].

CLINICAL PHENOTYPE AND INCLUSION CRITERIA

The initial therapeutic approach to COVID-19 hyperinflammatory state was based on previous experiences with other hyperinflammatory syndromes such as MAS/HLH. However, recent studies comparing characteristics between these two conditions have highlighted some differences. Compared to MAS/HLH, which is characterized by activation of an IL-18-interferon-γ axis, COVID-19 hyperinflammatory state is characterized by elevation of IL-1 receptor antagonist, intracellular adhesion molecule 1, and IL-8, as well as reduced levels of soluble Fas ligand [10]. Also, a study evaluating patients with COVID-19 hyperinflammation showed that they did not fulfill MAS/HLH classification criteria such as the HScore and 2004-HLH diagnostic criteria, despite having evident hyperinflammation features [11].

Two different sets of criteria for COVID-19 hyperinflammatory states have been proposed and validated (Table 1) [12**,13**]. In both studies, criteria identified patients at increased risk of prolonged hospitalization, mechanical ventilation, or death. Further studies are needed to better understand the ability of these criteria to discriminate potential benefits of anti-inflammatory therapy. Recently, these criteria have shown an association with hyperinflammation and worse outcomes in patients with rheumatic diseases [14*].

ANTIRHEUMATIC DRUGS FOR COVID-19

Glucocorticoids

Given the lack of benefits of glucocorticoids in infection-associated syndromes such as influenza, septic shock, and acute respiratory distress syndrome (ARDS), there was significant hesitancy regarding their use in patients with SARS-CoV-2 infection [15]. However, glucocorticoids were used from very early in the pandemic and observational studies showed mixed results [16].

Beneficial effects of dexamethasone for the treatment of severe COVID-19 were initially shown by the RECOVERY trial [17*]. In this open-label

| Table 1. Proposed criteria for COVID-19 hyperinflammatory syndrome |
|---------------------------------------------------------------|
| **Temple COVID-19 Cytokine Storm Criteria** | **COVID-19-associated hyperinflammatory syndrome (CHIS)** |
| Caricchio et al. [12**] | Webb et al. [13**] |
| **Signs/symptoms of COVID-19** | Fever > 38 °C |
| RT-PCR for COVID-19 | Ferritin > 700 ng/L |
| Ground-glass opacity by HRCT or chest Xray | Ferritin > 250 ng/ml |
| Ferritin > 4.6 mg/dL | CRP > 4.6 mg/dL |
| CRP > 4.6 mg/dL | Ferritin > 700 ug/L |
| Ferritin > 250 ng/ml | IL-6 > 15 pg/mL, or triglyceride > 150 mg/dL, or CRP > 15 mg/dL |
| Cluster 1 (one of the following): albumin < 2.8 g/dL, | Neutrophil to lymphocyte ratio > 10, or both hemoglobin ≤ 9.2 g/dL and platelet count ≤ 110 × 10⁹ per L |
| lymphocytes (%) < 10.2, neutrophil (absolute) | |
| > 11.4 K/mm³ | |
| Cluster 2 (one of the following): ALT > 60 U/L, | LDH > 400 U/L or AST > 100 U/L |
| AST > 87 U/L, D-dimer > 4,930 ng/ml, | |
| LDH > 416 U/L, Troponin I > 1.09 ng/ml | |
| Cluster 3 (one of the following): Anion gap < 6.8 mmol/L, | D-dimer > 1.5 ug/mL |
| chloride > 106 mmol/L, potassium > 4.9 mmol/L, | |
| BUN-creatinine ratio > 29 | |

RT-PCR, real time polymerase chain reaction; HRCT, high-resolution chest tomography; CRP, C-reactive protein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; IL-6, interleukin-6.
adaptive platform randomized controlled trial (RCT), dexamethasone 6 mg (PO or IV) daily for up to 10 days was shown to decrease mortality at 28 days (age-adjusted RR 0.83 [95% CI 0.74–0.92]) when compared to standard of care (SOC). This benefit was observed among patients who required mechanical ventilation (age-adjusted rate ratio (RR) 0.64 [95% CI 0.51–0.91]) or supplemental oxygen (age-adjusted RR 0.82 [95% CI 0.72–0.94]), but showed no benefit, and even concern for possible harm, among patients who did not require respiratory support (age-adjusted RR 1.19 [95% CI 0.91–1.55]). Since the release of RECOVERY, which led to changes in the treatment protocols for patients with COVID-19, several other studies have confirmed these findings using either different formulations (e.g., hydrocortisone, methylprednisolone) or dosing protocols (Table 2) [18–22]. A recent systematic review and meta-analysis of glucocorticoid treatment in COVID-19 showed a benefit of decreased mortality (odds ratio (OR) 0.66 [95% CI 0.52–0.82]) among all patients [23].

It is important to note that despite this encouraging data, registry studies of patients with autoimmune disease and baseline glucocorticoid use have shown an increased risk of severe COVID-19 with higher doses of glucocorticoids. Data from the COVID-19 Global Rheumatology Alliance (GRA) showed increased risks of both hospitalization and death in patients with baseline prednisone doses of 10 mg or higher [24,25]. Limitations to these registries, such as confounding by indication, limit the ability to fully disentangle these associations. However, these data, especially in conjunction with the RECOVERY findings in patients not on ventilatory support, may suggest that timing of intervention might be critical and that use of glucocorticoids could have a different effect depending on the phase of the disease.

**Colchicine**
Due to its ability to inhibit the NLRP3 inflammasome, leading to suppression of IL-1β, IL-18, and IL-6, colchicine has been proposed as a potential therapeutic for noncritically ill patients with COVID-19 [26]. An Italian cohort study using historical comparators receiving SOC, showed that patients treated with colchicine had a lower risk of death (hazard ratio (HR) 0.15 [95% CI 0.06–0.37]) [27]. Similar results were observed in another Italian single-center propensity score-matched cohort study, showing improving odds of discharge at day 28 and decreased overall mortality (9.1% vs 33.3%, OR 0.20 [95% CI 0.05–0.80]) [28].

An initial open-label RCT from Greece, the Greek Effects of Colchicine in COVID-19 (GRECCO-19) trial, compared colchicine vs SOC in 105 hospitalized COVID-19 patients [29]. The primary outcome, time to deterioration by 2 points in World Health Organization-Clinical Progression Scale (WHO-CPS), was longer in the colchicine arm compared to SOC (20.7 days vs 18.6 days, *P* = 0.03). No difference was observed in the other primary endpoints, including peak high-sensitivity troponin or resolution of CRP levels. Note that more clinically relevant outcomes would have been 30 and 60-day survival as the course of the disease was very heterogeneous and none of these parameters helped predict those at high risk of dying. Most recently, results from the Colchicine for community-treated patients with COVID-19 (COCORONA) trial, were published [30*]. In this multicenter RCT of 4488 patients with suspected or confirmed COVID-19 diagnosis, colchicine was administered at a dose of 0.5 mg twice per day for 3 days and later 0.5 mg daily for 27 days vs placebo. In the primary composite outcomes of hospitalization or death, a nonstatistically significant difference was observed (4.7% vs 5.8%, OR 0.79 [95% CI 0.61–1.03]). However, in the prespecified subgroup analysis of 4159 patients with PCR-confirmed COVID-19, a significant decrease in the primary endpoint was observed in patients treated with colchicine (4.6% vs 6.0%, OR 0.75 [95% CI 0.57–0.99]). This yielded a number needed to treat (NNT) of 70 (95% CI 36–1842). Except for a higher incidence of pulmonary embolism in the treatment arm, there were no differences in serious adverse events. The trial was terminated early due to logistical issues therefore potentially underpowering the conclusions. Although its use in high-risk patients might be convenient due to simple route of administration, low cost and relatively safe profile, the potential benefit on mortality is still unclear and will be hopefully clarified by several ongoing trials.

**Interleukin-6 inhibitors**
The initial associations between IL-6 elevation and COVID-19 severity sparked interest in the use of IL-6 inhibitors for the treatment of severe COVID-19. Initial observational studies showed promising results, and a meta-analysis including 16 studies showed a decreased risk of death (pooled OR 0.57 [95% CI 0.36–0.92]) associated with the use of tocilizumab (TCZ) compared to SOC [31]. Significant heterogeneity among studies was noted. Importantly, several of these studies focused on specific selection criteria that included documented infection with respiratory failure and markers of inflammation (e.g., CRP, ferritin) [32].

Despite encouraging data from observational studies, early RCTs did not confirm these earlier
### Table 2. Clinical trials assessing glucocorticoid treatment in patients with COVID-19

| Study/Sites       | Population          | Inclusion Criteria                                                                 | Intervention (dose, timing, duration) | Primary Endpoint | Results                                                                 | Observations                                                                 |
|-------------------|---------------------|------------------------------------------------------------------------------------|--------------------------------------|------------------|----------------------------------------------------------------------|----------------------------------------------------------------------------|
| RECOVERY          | Hospitalized patients | Suspected or confirmed SARS-CoV-2 infection                                         | Dexamethasone (PO/IV) 6 mg daily up to 10 days (n = 2104) vs SOC (n = 4321) | 28-day mortality | Reduced mortality with age-adjusted rate ratio 0.83 (95% CI 0.75 to 0.93) | Benefit observed only in patients requiring supplemental oxygen or mechanical ventilation |
| Horby et al. [17] | UK                  |                                                                                    |                                      |                  |                                                                      |                                                                            |
| REMAP-CAP         | ICU patients         | Suspected or confirmed SARS-CoV-2 infection and respiratory or cardiovascular organ support | IV Hydrocortisone fixed dose 50 mg or 100 mg q6h (n = 143) vs shock-dependent course 50 mg q6h (n = 152) vs SOC (n = 108) | Organ support-free (alive and free of ICU-based respiratory or cardiovascular support) days at 21 days | Superiority in both intervention arms with median organ support-free days of 0 (IQR -1 to 15) vs 0 (IQR -1 to 13) vs 0 (IQR -1 to 11), respectively | Bayesian analysis showing 93% and 80% probability of superiority for fixed-dose and shock-dependent dose, respectively, compared to SOC. Study stopped early due to RECOVERY results |
| Angus et al. [18] | North America, Europe, Australia |                                                                                      |                                      |                  |                                                                      |                                                                            |
| CAPE COVID        | ICU patients         | Suspected or confirmed SARS-CoV-2 infection and respiratory failure with at least 1 ventilatory criteria | IV hydrocortisone continuous infusion 200 mg/d for 7 days, then tapered by day 14 (n = 76) vs SOC (n = 73) | Treatment failure at day 21, defined as death or persistent dependency on mechanical ventilation or high-flow oxygen | 69 treatment failure events, 42.1% with hydrocortisone vs 50.7% with SOC (difference -8.6% [95% CI -24.9 to 7.7%]) | Study stopped early by DSMB, pending RECOVERY results. No differences in secondary outcomes including intubation, pronation or use of ECMO |
| Dequin et al. [20] | France               |                                                                                    |                                      |                  |                                                                      |                                                                            |
| CODEX             | ICU patients         | Suspected or confirmed SARS-CoV-2 infection on mechanical ventilation                | IV dexamethasone 20 mg daily for 5 days, then 10 mg daily for 5 days (n = 151) vs SOC (n = 148) | MV free-days at day 28 | Mean 6.6 ventilator-free days (95% CI 5.0–8.2) vs 4.0 ventilator-free days (95% CI 2.9–5.4) (difference -1.6, [95% CI -1.94 to -0.38]), respectively | No difference in secondary outcomes including all-cause mortality, or adverse events. Trial stopped early given RECOVERY results |
| Tomazini et al. [22] | Brazil               |                                                                                    |                                      |                  |                                                                      |                                                                            |
| GLUCOCOVID        | Hospitalized patients, non-ICU | Suspected or confirmed SARS-CoV-2 with symptoms for at least 7 days, X-ray evidence of pneumonia, abnormal gas exchange and evidence of systemic inflammatory response | IV methylprednisolone 40 mg BID for 3 days, then 20 mg BID for 3 days (n = 56) vs SOC (n = 29) | Composite outcomes of death, admission to ICU, or requirement of noninvasive ventilation | Relative risk 0.68 (95% CI 0.37 to 1.26) | 22 patients in the intervention arm were allocated by the treating physicians. 21 patients received other anti-inflammatory treatments |
| Corral-Gudino et al. [19] | Spain               |                                                                                    |                                      |                  |                                                                      |                                                                            |
observations (Table 3). The CORIMUNO-19 and COVACTA trials, which did not include inflammatory criteria for inclusion, failed to meet their primary endpoints [33,34]. The RCT-TCZ-COVID-19 and BACC BAY trials, which did include inflammatory criteria for inclusion, were potentially underpowered due to early stoppage or an unexpected low number of events, respectively [35,36]. More recent and larger RCTs, where most patients enrolled were also receiving background glucocorticoid treatment, have shown more positive results with regards to the use of IL-6 inhibition in severe COVID-19. The EMPACTA trial, which included 389 patients, showed a 44% decreased risk (HR 0.56 [95% CI 0.33–0.97]) of the composite outcomes of mechanical ventilation or death associated with the use of TCZ [37]. No improvement in all-cause death was observed. In the REMAP-CAP trial, that randomized patients to either TCZ, sarilumab or placebo, an improvement in organ support-free days and increased survival at 90 days were seen for both IL-6 inhibitors [38].

These results have been also confirmed by more recent trials including the RECOVERY trial. In the TCZ intervention arm from the RECOVERY adaptive platform, where 4116 patients were randomized to either TCZ or SOC, the risk of all-cause death was lower in patients treated with TCZ (adjusted RR 0.85 [95% CI 0.76–0.94]) [39]. Decrease in time to discharge and composite of mechanical ventilation and death was also lower in the intervention arm. These new findings, therefore, suggest benefits from the use of IL-6 inhibition, in addition to background glucocorticoid treatment, in patients with elevated markers of inflammation.

**Interleukin-1 inhibitors**

Transcriptomic analysis of whole blood of COVID-19 patients showed increasing expression IL-1α and IL-1β prior to the nadir of respiratory function, unlike other proinflammatory cytokines [40]. Also, given the clinical similarities between cytokine storm syndromes and COVID-19 hyperinflammation, use of IL-1 inhibitors for the treatment of severe COVID-19 was considered early in the pandemic [41–44].

Early case series and cohort studies suggested improvement in clinical outcomes of severe COVID-19 with anakinra, an IL-1 receptor antagonist. In a meta-analysis of two large cohort studies, anakinra was associated with a lower risk of mortality (pooled HR 0.2 [95% CI 0.1–0.4]) [16]. Despite these encouraging results, RCTs have not supported these observations (Table 4). The CORIMUNO-ANA-1 trial, a French multicenter open-label study, randomized patients to intravenous anakinra (200 mg BID on days 1–3, 100 mg BID on day 4, and 100 mg once on day 5)
| Study/Sites          | Design/Population  | Inclusion Criteria                                                                 | Intervention (dose, timing, duration) | Primary Endpoint | Results                                                                 | Observations                                                                                                                                                                                                 |
|---------------------|--------------------|-------------------------------------------------------------------------------------|---------------------------------------|------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| SARIRAF Della-Torre et al. [32] Italy | Open-label, not randomized/ Hospitalized | Confirmed SARS-CoV-2 infection with bilateral pneumonia with SpO2 ≤ 92% or PaFiO2 ≤ 300 mmHg and hyperinflammation (elevated LDH and one of the following: CRP ≥ 100 mg/ml, IL-6 ≥ 40 pg/ml, ferritin ≥ 900 ng/ml) | SAR 400 mg once (n = 28) vs SOC (n = 28) | Clinical improvement (WHO-CPS) and mortality at 28 days | No difference in clinical improvement (61% vs 64%, P = 0.94) or mortality (7% vs 18%, P = 0.21) | Median time to clinical improvement shorter in sarilumab treated patients (10 days vs 24 days, P = 0.01), SOC includes antiviral, hydroxychloroquine and antibiotic therapy. |
| CORIMUNO-19 Hermine et al. [33] France | Open-label RCT/ Hospitalized non-ICU patients | Confirmed SARS-CoV-2 with moderate, severe or critical pneumonia (O2 > 3L/min) (intubation excluded) | IV TCZ 8 mg/kg single dose (n = 64) vs SOC (n = 67), Option of second dose at 72h | Score ≥ 5 on WHO-CPS at day 4 and intubation or death at day 14 | No difference in WHO-CPS (ARD -9.0% [90% CI -21.0 to 3.1]) On day 14, 24% with TCZ vs 36% with SOC (HR 0.58 [90% CI 0.33–1.00]) | No difference on intubation or death at day 28. 17% of patients with background glucocorticoids. |
| RCT-TCZ-COVID-19Salvarani et al. [36] Italy | Open-label RCT/ Hospitalized non-ICU patients | Confirmed SARS-CoV-2 with PaFiO2 200–300 mmHg and inflammatory phenotype: fever (> 38°C) last 2 days and/or CRP ≥ 10 mg/dl or CRP doubled since admission | IV TCZ 8 mg/kg single dose (n = 60) vs SOC (n = 66), Option of second dose at 12h | Composite outcome of clinical worsening including MV, death or PaFiO2 < 150 mmHg | 28.3% with TCZ vs 27.0% in SOC (RR 1.05 [95% CI 0.59–1.86]) | Stopped early due to futility on interim analysis. |
| BACC BAY Stone et al. [35] US | Double-blinded RCT/ Hospitalized non-ICU patients | Confirmed SARS-CoV-2 with at least 2 of the following: fever (> 38°C) within 72h of enrollment, pulmonary infiltrates, supplementary oxygen to maintain SpO2 ≥ 92%, and one of the following: CRP > 50 mg/L, ferritin > 500 ng/ml, D-dimer > 1000 ng/ml, LDH > 250 U/L | IV TCZ 8 mg/kg single dose (n = 161) vs SOC (n = 82) | MV or death (time-to-event) | 17 events with TCZ vs 10 events in SOC (HR 0.83 [95% CI 0.38–1.81]) | No benefit for secondary outcome of clinical worsening (HR 1.11 [95% CI 0.59–2.10]) Possibly underpowered due to the low number of events. |

Table 3. Studies assessing Interleukin-6 inhibitor treatment in patients with COVID-19
| Study/Sites | Design/Population | Inclusion Criteria | Intervention (dose, timing, duration) | Primary Endpoint | Results | Observations |
|-------------|-------------------|--------------------|---------------------------------------|------------------|---------|--------------|
| TOCIBRAS Veiga et al. [73] Brazil | Open-label RCT/Hospitalized patients | Confirmed SARS-CoV-2 with supplemental oxygen or mechanical ventilation and at least two of the following: D-dimer > 1000 ng/ml, CRP > 5 mg/dl, ferritin > 300 ug/L, or LDG > ULN | IV TCZ 8 mg/kg single dose (n = 65) vs SOC (n = 64) | Clinical status (ordinal scale) at day 15 | Patients on MV or deaths: 28% with TCZ vs 20% with SOC (OR 1.54 [95% CI 0.66–3.66]) | No differences in 28 day or in-hospital mortality, 71% of patients on glucocorticoids. |
| EMPACTA Salama et al. [37] North and South America | Double-blinded RCT/Hospitalized patients non-ICU | Confirmed SARS-CoV-2 receiving supplemental oxygen (noninvasive or invasive ventilation excluded) | IV TCZ 8 mg single dose (n = 259) vs SOC (n = 128). Option for second dose 8–24h | MV or death at day 28 | 12% with TCZ vs 19.3% with SOC (HR 0.56 [95% CI 0.33–0.97]) | No improvement on death from any cause. Clinical failure assessed in time-to-event analysis favored TCZ. Majority of patients on glucocorticoids (>80%) and antiviral therapy (>70%). |
| COVACTA Rosas et al. [34] North America and Europe | Double-blind RCT/Hospitalized patients | Confirmed SARS-CoV-2 with SpO2 ≤ 93% or PaFiO2 < 300 mmHg | IV TCZ 8 mg single dose (n = 301) vs SOC (n = 151). Option for second dose 8–24h | Clinical status (7-category ordinal scale) at day 28 | Median value for clinical status on ordinal scale 1.0 with TCZ vs 2.0 with SOC (between group difference -1.0 [95% CI -2.5 to 0]) | No difference in mortality at day 28. 37% on invasive MV at baseline. |
| REMAP-CAP Gordon et al. [38*] Multiple countries | Open-label RCT/ICU patients | Suspected or confirmed SARS-CoV-2 on respiratory or cardiovascular organ support | IV TCZ 8 mg/kg single dose (n = 353) or IV SAR 400 mg (n = 48) vs SOC (n = 402) | Organ support free days at day 21 | Median number of organ support free days 10 with TCZ [OR 1.64 [95% CI 1.25 to 2.14] for TCZ], 11 with SAR [OR 1.76 [95% CI 1.17–2.91]] vs 0 with SOC | Improved survival at 90 days for TCZ or SAR treated patients. > 80% of patients on glucocorticoids. |
| Study/Sites | Design/Population | Inclusion Criteria | Intervention (dose, timing, duration) | Primary Endpoint | Results | Observations |
|-------------|------------------|--------------------|---------------------------------------|------------------|---------|--------------|
| Lescure et al. [74] Multiple countries | Double-blind RCT/ Hospitalized patients | Confirmed SARS-CoV-2 with severe (oxygen supplementation) or critical (noninvasive and invasive ventilation) disease | IV SAR 400 mg single dose (n = 173) vs IV SAR 200 mg (n = 161) vs SOC (n = 86). Option for a second dose 24–48h | Time to clinical improvement of ≥ 2 points (7-category ordinal scale) | Median time to improvement 10 days with SAR 400 mg (HR 1.14 [95% CI 0.83–1.54]) vs 10 days with SAR 200 mg (HR 1.03 [95% CI 0.75–1.40]) vs 12 days with SOC | No difference in survival. |
| COVINTOC Soin et al. [75] India | Open-label RCT/ Hospitalized | Confirmed SARS-CoV-2 with moderate (RR 15–30/min and SpO2 90–94%) or severe (RR > 30/min and SpO2 < 90%) or ARDS or septic shock | IV TCZ 6 mg/kg (n = 90) vs SOC (n = 90). Option for second dose at 12h to 7d | Progression from moderate to severe, or severe to death up to day 14 | Progression in 9% with TCZ vs 13% with SOC (mean difference -3.71 [95% CI -18.23 to 11.19]) | 91% of patients on glucocorticoids. |
| RECOVERY Abani et al. [39**] UK | Open-label RCT/ Hospitalized patients | Suspected or confirmed SARS-CoV-2 with hypoxia (SpO2 < 92%) and CRP ≥ 75 mg/L | IV TCZ 400–800 mg (n = 2022) vs SOC (n = 2094) | All-cause death at day 28 | 31% with TCZ vs 35% with SOC (aRR 0.85 [95% CI 0.76–0.94]) | Decrease in time to discharge and composite of MV or death (in non-MV patients at baseline). 80% patients on glucocorticoids. |

IV, intravenous; SOC, standard of care; ICU, intensive care unit; IQR, interquartile range; SpO2, oxygen saturation; PaO2/FiO2, ratio of arterial oxygen partial pressure to fractional inspired oxygen; TCZ, tocilizumab; SAR, sarilumab; CI, confidence interval; CrI, credible interval; HR, hazard ratio; OR, odds ratio; aRR, adjusted relative risk; WHO-CPS, World Health Organization Clinical Progression Scale; CRP, C reactive protein; LDH, lactate dehydrogenase; RR, respiratory rate; ARDS, acute respiratory distress syndrome.
| Study/Sites          | Design/Population | Inclusion Criteria                                                                 | Intervention (dose, timing, duration) | Primary Endpoint                        | Results                                                                 | Observations                                                                 |
|---------------------|-------------------|-------------------------------------------------------------------------------------|---------------------------------------|----------------------------------------|--------------------------------------------------------------------------|----------------------------------------------------------------------------|
| CORIMUNO-ANA-1     | RCT/Hospitalized patients non-ICU, France | Confirmed SARS-CoV-2 infection with mild-moderate, severe or critical pneumonia and CRP > 25 mg/L | IV Anakinra 200 mg BID on day 1-3, then 100 mg BID day 4 and 100 mg day 5 (n = 59) vs SOC (n = 57), Additional doses given if no improvement after day 4 | Score > 5 on WHO-CPS at day 4 or composite outcome of MV or death at day 14 | WHO-CPS >5 at day 4: 36% with anakinra vs 38% with SOC (ARD -2.5% [90% CrI -17.1 to 12.0]) MV or death at day 14: 47% with anakinra vs 51% with SOC [HR 0.97 [90% CrI 0.62–1.52]] | Study stopped early by recommendation of DSMB.                                |
| SAVE               | Open-label nonrandomized with parallel controls, Hospitalized patients non-ICU, Greece | Confirmed SARS-CoV-2 infection, imaging consistent with pneumonia and plasma suPAR levels > 6 ng/ml | SC anakinra 100 mg daily for 10 days (n = 130) vs SOC (n = 179) | Severe respiratory failure at day 14 | 22.3% with anakinra vs 59.2% with SOC [HR 0.30 [95% CI 0.20–0.46]] | Parallel controls chosen by propensity-score matching. Decrease mortality.                  |
| OMACOVID-19        | Prospective, open-label interventional study, Hospitalized patients, Oman | Confirmed SARS-CoV-2 infection, imaging consistent with bilateral pneumonia, and at least one of the following: RR >30/min and SpO2 < 90% on RA, SpO2 ≤ 93% on oxygen ≥ 6L/min, ARDS | SC anakinra 100 mg BID for 3 days, then 100 mg daily for 7 days (n = 45) vs SOC (n = 24) | MV and in-hospital death | MV: 31% with anakinra vs 75% with SOC [P < 0.001], In-hospital death: 29% with anakinra vs 46% SOC [P = 0.082] | Historical controls. 60% on glucocorticoids.                                  |
| CAN-COVID          | RCT/Hospitalized patients non-ICU, US and Europe | Confirmed SARS-CoV-2 infection, imaging consistent with pneumonia, SpO2 ≤ 93% on RA or PaO2 < 300 mmHg, and CRP ≥ 20 mg/L or ferritin ≥ 600 µg/L | Canakinumab weight-based single dose vs SOC | Survival without MV at day 28 | 88% with canakinumab vs 85.7% with SOC [P = 0.29] | No difference in mortality. Interim analysis, pending final publication. |

IV, intravenous; SOC, standard of care; ICU, intensive care unit; SpO2, oxygen saturation; suPAR, soluble urokinase plasminogen activator receptor; CI, confidence interval; CrI, credible interval; HR, hazard ratio; OR, odds ratio; ARD, absolute risk difference; ARDS, acute respiratory distress syndrome; WHO-CPS, World Health Organization Clinical Progression Scale; CRP, C reactive protein.
or to SOC in patients with COVID-19 requiring at least 3L/min \( \text{O}_2 \) and a CRP greater than 25 mg/L [45]. The study was stopped early by recommendation of the data safety monitoring board, and no differences were found in the primary outcomes of improvement in clinical status at day 4 or need for mechanical ventilation or death at day 14. The Anakinra for COVID-19 Respiratory Symptoms (ANACONDA) study was also stopped early due to concern for worse outcomes in the intervention arm [46]. Results of this study are not available. Interestingly, a Greek open-label interventional study that allocated treatment with anakinra to patients with COVID-19 and elevated levels of soluble urokinase plasminogen activator receptor (suPAR) showed a decrease in mechanical ventilation in patients treated with anakinra [47].

Treatment with canakinumab, an IL-\( \beta \) inhibitor, has also been assessed in small case series and in larger studies. The CAN-COVID study, a phase 3 trial, randomized patients to either canakinumab or SOC [48]. Although results of the study have not been published, a press release in November 2020 announced that the study did not achieve its primary endpoint of improvement in survival without mechanical ventilation at day 28. Currently, the role of IL-1 inhibitors for the treatment of COVID-19 is not clear, and hopefully ongoing phase 3 clinical trials will better clarify this point.

**Tumor necrosis factor \( \alpha \) inhibitors**

Based on observations of elevated TNF-\( \alpha \) levels in patients with severe COVID-19, there is growing interest regarding the use of TNF-inhibitors for the treatment of COVID-19 [49]. In fact, a role for TNF inhibition in animal models of other viral lung diseases such as influenza has been proposed [50]. These mechanistic observations have also been reinforced by lower odds of severe COVID-19 in patients on baseline TNF-inhibitors such as rheumatic and inflammatory bowel disease patients [51]. Currently, five ongoing trials utilizing infliximab in hospitalized COVID-19 patients and one using adalimumab in ambulatory COVID-19 patients are ongoing (Table 5).

### Table 5. Ongoing studies assessing tumor necrosis factor (TNF)-\( \alpha \) inhibitor treatment in patients with COVID-19

| Drug          | Clinical Trials.gov Identifier | Design/Setting                  | Intervention | Inclusion criteria                                                                 | Primary outcome |
|---------------|--------------------------------|---------------------------------|--------------|------------------------------------------------------------------------------------|----------------|
| Infliximab    | NCT04425538                    | Single group assignment/        | IV Infliximab 5 mg/kg. Option for second dose 7–21 days | Confirmed SARS-CoV-2 infection, pneumonia evidenced by imaging and at least one of the following: RR \( \geq \) 30/min, SpO2 \( \leq \) 93% on RA, PaFiO2 < 300, worsening lung involvement | Time to improvement in oxygenation |
| Infliximab    | NCT04734678                    | Cohort/Hospitalized patients    | IV TCZ 400 mg single dose vs IV TCZ 400 mg single dose + IV Infliximab 5 mg/kg/d for 2 doses | Confirmed SARS-CoV-2 infection, pneumonia evidenced by imaging, hyperinflammation (either CRP \( \geq \) 100 mg/L, ferritin \( \geq \) 900 mg/ml with LDH > 220 U/L) and at least one of the following: RR \( \geq \) 30/min, SpO2 \( \leq \) 93% on RA, PaFiO2 < 300, involvement | Clinical status improvement (6 category scale) |
| Infliximab    | NCT04593940                    | RCT/Hospitalized patients       | IV Infliximab 5 mg/kg single dose vs SOC | Confirmed SARS-CoV-2 infection with ongoing illness and at least one of the following: radiographic infiltrates, SpO2 \( \leq \) 94% RA, supplemental oxygen requirement, MV or ECMO | Time to recovery by day 29 |
| Infliximab    | NCT04381936                    | RCT/Hospitalized patients       | IV infliximab 5 mg/kg single dose vs SOC | Suspected or confirmed SARS-CoV-2 infection | All-cause mortality |
| Adalimumab    | NCT04705844                    | RCT/Nonhospitalized patients    | SC Adalimumab 160 mg (40 mg, 4 doses) vs SOC | Confirmed SARS-CoV-2, COVID-19 related symptoms, SpO2 \( \geq \) 93%, and at least one of the following: CRP > 50 mg/L, lymphopenia < 1.5 x 10\(^7\)/L, neutrophilia > 7.5 x 10\(^7\)/L | Rate of progression to severe disease or death |

IV, intravenous; SC, subcutaneous; SOC, standard of care; ICU, intensive care unit; SpO2, oxygen saturation; PaFiO2, ratio of arterial oxygen partial pressure to fractional inspired oxygen; TCZ, tocilizumab; CRP, C reactive protein; LDH, lactate dehydrogenase; RR, respiratory rate; MV, mechanical ventilation; ECMO, extracorporeal membrane oxygenation.
Janus kinase inhibitors
For the treatment of COVID-19 infection, JAK inhibitors have two proposed mechanisms of action: inhibition of viral entry to cells through disruption of AAK1 and decreased signaling of pro-inflammatory cytokines, such as IL-2, IL-6, and IFN-γ, through inhibition of the JAK-STAT pathway [9,52]. A meta-analysis of observational studies using baricitinib and ruxolitinib for the treatment of COVID-19 showed lower odds of mortality, ICU admission, and higher odds of discharge associated with treatment. It is important to note that studies included were observational and presented significant heterogeneity [53]. The Adaptive COVID-19 Treatment Trial 2 was the first published double-blind RCT comparing baricitinib against placebo (with background remdesivir) [54**]. In this trial of 1033 hospitalized patients, those treated with baricitinib had a shorter time to recovery (7 vs 8 days, \(P = 0.03\)) and higher odds of clinical improvement (OR 1.3 [95% CI 1.0–1.6]). A nonsignificant trend toward lower mortality at day 28 was also noted. Most recently, the preprint results of a large global RCT of 1525 hospitalized patients showed no difference in its primary outcome of reduction of disease progression (OR 0.86 [95% CI 0.67–10.8]) [55]. However, a 38.2% reduction in mortality was observed in all prespecified groups. In both trials, no difference in venous thromboembolic events was noted.

Interestingly, similar to glucocorticoids, baseline use of JAK inhibitors has been associated with worse COVID-19 outcomes. A recent analysis of a large cohort of rheumatoid arthritis (RA) patients showed that use of JAK inhibitors was associated with a higher risk of worse COVID-19 severity (OR 1.52 [95% CI 1.02–2.28]) compared to TNF inhibitors [56]. These findings may be associated with inhibition of the interferon pathway which is necessary for the clearance of viral infections, and may also speak to the importance of timing of the intervention. Results from the ongoing trial will provide further information regarding the use of these drugs for the treatment of COVID-19 (Table 6).

Granulocyte-monocyte colony-stimulating factor inhibitors
Granulocyte-monocyte colony stimulating factor (GM-CSF) inhibiting therapies are currently being studied for the treatment of rheumatic diseases such as RA and giant cell arteritis [57,58]. GM-CSF has been associated with severe COVID-19, and elevated levels have been associated with markers of endothelial injury and thrombosis [59]. Bronchoalveolar lavage fluid analysis from patients with severe COVID-19 has shown high levels of Th-17 cells associated with an overexpression of GM-CSF and IL-17A [60].

An initial study with lenzilumab (600 mg IV for three doses) in 12 patients with severe COVID-19 showed a faster improvement in clinical outcomes when compared to a matched control cohort receiving SOC (5 days vs 11 days, \(P = 0.06\)) [61]. Although clinical improvement was similar in both groups, the proportion of patients with ARDS was also reduced with lenzilumab treatment. The first published RCT assessing the use of a GM-CSF inhibitor, mavrilimumab, randomized patients to mavrilimumab vs SOC [62]. The Mavrilumab in patients with severe COVID-19 pneumonia and systemic hyper-inflammation (MASH-COVID) study included hospitalized patients with COVID-19 pneumonia, hypoxemia, and CRP > 5 mg/dl. The primary outcome of survival without supplementary oxygen at day 14 was not different between the two groups (57% vs 47%, OR 1.48 [95% CI 0.43–5.16]. The results of this study were underpowered due to early termination after slow recruitment. Preprint results of two larger trials, LIVE-AIR (with lenzilumab) and OSCAR (otilimab), and ongoing studies will further clarify the role of GM-CSF inhibitors as treatment options for severe COVID-19 [63,64].

Anticomplement therapy
Complement activation has been shown to play a central role in the pathophysiology of both ARDS and macrovascular thrombosis. Endothelial injury secondary to activation of anaphylatoxins (C3a, C4a, and C5a) is a key component in the pathway of both of these complications [65]. Even more so, increased complement activation seems to be a distinctive feature of severe COVID-19 as shown by significant elevation of circulating markers of complement activation when compared to patients with other critical conditions, including influenza infection [66].

Use of eculizumab, a C5 inhibitor, for the treatment of severe COVID-19 has been described in several case reports. Eculizumab (900 mg, 2 doses) in addition to SOC was associated with recovery of four patients with severe COVID-19 [67]. In a non-randomized controlled study of 80 patients with severe COVID-19, 35 patients treated with eculizumab vs 45 patients receiving SOC, patients treated with eculizumab had a higher survival at day 15 (82.9% vs 62.2%, \(P = 0.04\)) [68]. A phase 2 trial of IFX-1, a C5a inhibitor, showed no difference in its primary outcome of percentage change in PaO2/FIO2, but showed a nonsignificant trend toward improved survival and decreased pulmonary embolisms [69]. Further knowledge of anticomplement therapies,
including identification of biomarkers of patients who would benefit from these, are needed.

**CONCLUSION**

The unprecedented challenge of the global COVID-19 pandemic has rightfully monopolized the attention of the entire medical field. The hyperinflammatory features of severe COVID-19, somehow resembling those of rheumatic and cytokine storm syndromes, have placed both rheumatologists and the immunomodulatory medications used for the treatment of rheumatic diseases in a unique position. The successful use of glucocorticoids such as dexamethasone for the

---

**Table 6. Ongoing phase 3 or 4 randomized controlled trials assessing Janus Kinase inhibitor treatment in patients with COVID-19**

| Clinical Trials.gov Identifier/Study | Design               | Intervention                                      | Inclusion criteria                                                                                     | Primary outcome                                           |
|-------------------------------------|----------------------|---------------------------------------------------|--------------------------------------------------------------------------------------------------------|----------------------------------------------------------|
| NCT04421027                         | RCT/Hospitalized non-ICU | BARI 4 mg PO daily vs SOC | Confirmed SARS-CoV-2 infection, supplemental oxygen requirement, and at least one inflammatory marker > ULN: CRP, d-dimer, LDH, ferritin | Death or requirement of noninvasive ventilation/HFNC or MV |
| NCT04358614                         | RCT/Hospitalized patients | BARI 4 mg PO daily for 14 d + antiviral vs antiviral | Confirmed SARS-CoV2, radiographic infiltrates, SpO2 > 92%, PaO2 > 100–300 mmHg | Safety in terms of serious and nonserious adverse events |
| NCT04832880                         | RCT/Hospitalized patients non-ICU | Dexamethasone (SOC) vs Remdesivir + SOC vs BARI 4 mg PO for 10 days + SOC vs Remdesivir + BARI + SOC | Confirmed SARS-CoV2 infection, <10 days of symptom onset and Temple COVID-19 CS criteria | Composite outcome of Very severe respiratory failure (PaO2 < 150 mmHg) or mortality |
| NCT04693026                         | RCT/ ICU patients | Remdesivir + BARI 4 mg PO 14 days vs Remdesivir + TCZ | Confirmed SARS-CoV2 infection, admission ICU | Time to clinical improvement |
| NCT04640168                         | RCT/Hospitalized patients non-ICU | Remdesivir + BARI 4 mg PO 14 days vs Remdesivir + Dexamethasone | Confirmed SARS-CoV2 infection, new oxygen requirement within past 7 days | Survival without MV and death |
| NCT04390464                         | RCT/Hospitalized patients non-ICU | BARI 4 mg PO 14 days vs Ravulizumab vs SOC | Confirmed SARS-CoV2 infection and severe disease | Time of incidence to composite endpoint of death, MV, ECMO, CV organ support or renal failure |
| NCT04890626                         | RCT/ Hospitalized patients | BARI + dexamethasone vs dexamethasone (SOC) | Confirmed SARS-CoV2 infection | Death at day 28 |
| NCT04891133                         | RCT/Hospitalized patients | BARI 4 mg PO 14 days + SOC | Confirmed SARS-CoV2 infection + moderate-severe disease | Death at day 60 |
| NCT04381936                         | Open label RCT/ Hospitalized patients | BARI 4 mg PO 10 days + SOC | Suspected or confirmed SARS-CoV2 infection | All-cause mortality at day 28 |
| NCT04424056                         | Open label RCT/ Hospitalized patients | Ruxolitinib +/- TCZ or Anakinra vs SOC | Confirmed SARS-CoV2 infection and hypoxemic pneumonia with CRP > 150 ng/ml or PaO2 < 300 or PaO2 < 200 with another organ failure | Ventilation free days at day 28 |

RCT, randomized controlled trial; BARI, baricitinib; SOC, standard of care; ICU, intensive care unit; SpO2, oxygen saturation; PaO2, ratio of arterial oxygen partial pressure to fractional inspired oxygen; TCZ, tocilizumab; CRP, C reactive protein; MV, mechanical ventilation; ECMO, extracorporeal membrane oxygenation; CV, cardiovascular.
Role of immunomodulatory medications Sattui et al.

The impacts of COVID-19 have shown the benefits of immunomodulation. Interestingly, observations such as those from the RECOVERY trial and large registries of patients with baseline glucocorticoid use (similar to JAK inhibitors), highlight the importance of timing of intervention. Even more so, studies have also shown the role of host characteristics, such as inborn errors in type I IFN immunity, therefore highlighting the need to better characterize patients at risk of COVID-19 hyperinflammation and potentially those who would benefit the most from immunomodulatory interventions [70*,71**].

Challenges to research during the COVID-19 pandemic have also left several valuable lessons that should be incorporated in future scenarios. As shown in this review, discordant results of trials assessing the same drug could be potentially explained by lack of uniform selection criteria, changes in definitions of SOC or changes in timing, dosages or duration of interventions. Understandably, the dynamic nature of the pandemic and knowledge generated has led to some of these limitations. However, coordinated efforts such as the RECOVERY adaptive trial platform have led to invaluable knowledge.

Although glucocorticoids have an established role in the treatment of severe COVID-19, other immunomodulatory therapies such as JAK inhibitors, particularly baricitinib, and IL-6 might require further studies despite some encouraging results. Particularly, studies are needed to better identify patients who would benefit from these interventions. Hopefully, ongoing RCTs or studies utilizing proposed COVID-19 hyperinflammatory phenotypic criteria will shed some light on this matter as well the role of other DMARDs such as IL-1, GM-CSF and complement inhibitors. Although approved vaccines are helping to mitigate the pandemic, the need to identify better treatment options for patients with severe COVID-19 and complications such as COVID-19 hyperinflammation remains crucial.

Acknowledgements

None.

Financial support and sponsorship

None.

Conflicts of interest

I.N.M. was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH (grant K23-AR-068449) and has received speaker fees from Sobi. S.E.S.’s work was supported by the Vasculitis Clinical Research Consortium-Vasculitis Foundation Fellowship award (grant US4-AR-057319) outside of submitted work. Remaining authors have no conflicts of interest.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

■ of special interest

■ of outstanding interest

1. Coronavirus disease 2019 dashboard: World Health Organization. Available at: https://covid19.who.int/. [Accessed 1 June 2021]

2. Domingo P, Mur I, Pomar V, et al. The four horsemen of a viral Apocalypse: the pathogenesis of SARS-CoV-2 infection (COVID-19). EBioMedicine 2020; 58:102887.

3. Mangalmurti N, Hunter CA. Cytokine storms: understanding COVID-19. Immunity 2020; 53:19–25.

4. Review of COVID-19 and cytokine storms.

5. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed patients with rheumatic diseases.

6. Bzdzenski U, Dzsungel G, Oral E, et al. Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy 2020; 75:2829–2845.

7. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease. J Clin Invest 2020; 130:2620–2629.

8. This article describes the differences in immunological features between moderate and severe COVID.

9. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science 2020; 368:473–474.

10. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med 2020; 8:e44–e47.

11. Zhang X, Zhang Y, Gao W, et al. Baricitinib, a drug with potential effect to counteract the cytokine storm induced by COVID-19. Int Immunopharmacol 2020; 86:106749.

12. Kessel C, Vollenberg R, Masjoosthussmann K, et al. Discrimination of COVID-19 from inflammation-induced cytokine storm syndromes by disease-related blood biomarkers. Arthritis Rheumatol 2021. DOI: 10.1002/art.41763 [Epub ahead of print]

13. Lorenz G, Moog P, Bachmann Q, et al. Title: Cytokine release syndrome is not usually caused by secondary hemophagocytic lymphohistiocytosis in a cohort of 19 critically ill COVID-19 patients. Sci Rep 2020; 10:18277.

14. Caricchio R, Gallucci M, Dass C, et al. Preliminary predictive criteria for COVID-19 cytokine storm. Ann Rheum Dis 2021; 80:89–95.

15. Proposed set of criteria and validation for evaluation of COVID-19 cytokine storm.

16. Webb BJ, Peltan ID, Jensen P, et al. Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study. Lancet Rheumatol 2020; 2:e765–e769.

17. Proposed set of criteria and validation for evaluation of COVID-19 cytokine storm.

18. Hsu TT, D’Silva RM, Patel NJ, et al. Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study. Lancet Rheumatol 2021. DOI: 10.1016/S2665-9913(21)00140-5 [Epub ahead of print]

19. Study evaluating features of hyperinflammation and association with outcomes in patients with rheumatic diseases.

20. Shang L, Zhao J, Hu Y, et al. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 2020; 395:683–684.

21. Putman M, Chock YPE, Tam H, et al. Antirheumatic disease therapies for the treatment of COVID-19: a systematic review and meta-analysis. Arthritis Rheumatol 2021; 73:36–47.

22. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021; 384:693–704.

23. RECOVERY trial showing benefit of glucocorticoids in the treatment of COVID-19.

24. Angus DC, Derde L, Al-Beidh F, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: The REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA 2020; 324:1317–1329.

25. Corral-Gudino L, Bahamonde A, Arnaiz-Reivillas F, et al. Methylprednisolone or dexamethasone in critically ill patients with COVID-19: a randomized clinical trial. JAMA 2020; 324:1298–1306.

26. Ranbar K, Moghadami M, Mirahmadsadadi A, et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis 2021; 21:337.
Rheumatological aspects and treatments of COVID-19

22. Tomazini BM, Mais IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: The CoDEx Randomized Clinical Trial. JAMA 2020; 324:1307–1316.

23. Sterne JAC, Murthy S, Daz IV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a network meta-analysis. JAMA 2020; 324:1300–1314.

24. Gianfrancesco M, Yuan J, Robinson PC. Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases. Curr Opin Rheumatol 2020; 32:434–440.

25. Strangfeld A, Schäfer M, Gianfrancesco MA, et al. Factors associated with COVID-19 related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2021; 8:930–942.

26. Reyes AZ, Hu KA, Teperman J, et al. Anti-inflammatory therapy for COVID-19 infection: the case for colchicine. Ann Rheum Dis 2020. DOI: 10.1136/annrheumdis-2020-201914 [Epub ahead of print].

27. Scarsi M, Plantron S, Colombo E, et al. Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. Ann Rheum Dis 2020; 79:1286–1289.

28. Brunetti L, Diawara O, Tsai A, et al. Colchicine to weather the cytokine storm in hospitalised patients with COVID-19. J Clin Virol 2020; 125:104361.

29. Defteros SG, Giannopoulous G, Vrachatis DA, et al. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients with COVID-19: results from the GREECO-19 Randomized Clinical Trial. JAMA Netw Open 2020; 3:e2013136.

30. Tarf JD, Bouabdallahu N, L’Allier PL, et al. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blind, adaptive, placebo-controlled, multicentre trial. Lancet Respir Med 2021. DOI: 10.1016/S2213-2600(20)20022-8 [Epub ahead of print].

31. Salvarani C, Dolci G, Massari M, et al. Association between administration of GM-CSF neutralization with increased complement activation in severe COVID-19: a prospective cohort study. EClinicalMedicine 2020; 21:100435.

32. Gordon AC, Mouncey PR, Al-Beidh F, et al. Targeting granulocyte-monocyte colony-stimulating factor signaling in rheumatoid arthritis: future prospects. Drugs 2019; 79:1741–1755.

33. Sterne JAC, Perissi A, Nantaja A, et al. Addition of tocilizumab to the standard of care reduces mortality in severe COVID-19: a systematic review and meta-analysis. Front Med 2020; 7:586221.

34. Dell’Orto E, Campanacci C, Cavi G, et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis 2020; 79:1277–1285.

35. Hermoe O, Mariette X, Tharaux PL, et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med 2021; 181:32–40.

36. Rosas IO, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with severe COVID-19 pneumonia. N Engl J Med 2021; 384:1503–1516.

37. Stone JH, Frigui ML, Serfing-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with COVID-19. N Engl J Med 2020; 383:2333–2344.

38. Salvador MD, Dolci G, Massari M, et al. Efficacy of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med 2021; 181:24–31.

39. Salvarani C, Han J, Jau L, et al. Tocilizumab in patients hospitalized with COVID-19 pneumonia. N Engl J Med 2021; 384:20–30.

40. Gorden AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 receptor antagonists in critically ill patients with COVID-19: results from the RECOVERY study showing benefit of addition to tocilizumab for the treatment of COVID-19. Medicine 2021; 100:062768.

41. Pate I, Beshuizen A, Ruiz XB, et al. A randomized trial of tocilizumab vs usual care for COVID-19 pneumonia (CORIMUNO-19 Collaborative group). Effect of anakinra versus usual care in patients with COVID-19 pneumonia and acute respiratory distress syndrome: Results from the IMUNO-ANA-1: a randomised controlled trial. Lancet Respir Med 2020; 3:e764–e773.

42. Mehta P, Chambers RC, Dagna L. Granulocyte-macrophage colony stimulating factor in COVID-19: friend or foe? Lancet Rheumatol 2021; 3:e394–e395.

43. Temesgen Z, Assi M, Shweta FNU, et al. GM-CSF neutralization with lenzilumab in severe COVID-19 pneumonia: a case-subject cohort study. Mayo Clin Proc 2020; 95:2382–2394.

44. Kremer PC, Abbate A, Hubock K, et al. Novel management of patients with COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Rheumatol 2021; 3:e410–e418.

45. Zhang J, Xu J, Zhan Y, et al. A randomized trial of tocilizumab in severe COVID-19 pneumonia (OSCARi, medRxiv 2021. DOI: 10.1101/ 2021.04.14.21255475 [Epub ahead of print].

46. Temesgen Z, Burger CD, Barwick J, et al. Lenzilumab efficacy and safety in newly hospitalized COVID-19 subjects: results from the LIVE-AIR phase 3 randomized double-blind placebo-controlled trial. medRxiv 2021. DOI: 10.1101/2021.05.01.212266470 [Epub ahead of print].

47. Java A, Apicelli AJ, Liszewska MK, et al. The complement system in COVID-19: friend and foe? JCI Insight 2020; 5:e140711.

48. Novartis provides update on CAN-COVID trial in hospitalised patients with COVID-19 and cytokine release syndrome (CRS). Available at: https://www.novartis.com/news-media/releases/novartis-provides-update-on-cantcovid-trialhospitalized-patients-covid-19-pneumonia-and-cytokine-releasessoridy-crs. [Accessed 31 May 2021]

49. Moradian N, Gouravani M, Salehs MA, et al. Cytokine release syndrome: inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality. Eur Cytokine Netw 2020; 31:81–93.

50. Russell TW, Perrycook A, Lansfargh P. Inhibition of tumor necrosis factor reduces the risk of serious virus-specific lung immunopathology. Eur J Immunol 2001; 31:2566–2573.

51. Robinson PG, Liew DFL, Liew JW, et al. The potential for repurposing anti-TNF as a therapy for the treatment of COVID-19. Medicine 2020; 99:1–10.

52. Arnett FC, Makk A, Chen HW, et al. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the Global Rheumatology Alliance physician registry. Ann Rheum Dis 2021. DOI: 10.1136/annrheumdis-2021-220418 [Epub ahead of print].

53. Temesgen Z, Sánchez Sevilla Uruchurtu A, Siggins MK, et al. Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. Sci Immunol 2021; 6:eabg9873.

54. Vlah A, Bruni N, Busch M, et al. Anti-CSA antibody IFX-1 (veloblimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. Lancet Rheumatol 2020; 2:e677–e688.

55. Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 2020; 370: 705–709.

56. Studying association between specific type I IFN antibodies and association with severe COVID-19.
71. Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 2020; 370:eabd4570. Study showing association between specific IFN gene mutations and severe COVID-19.

72. Jeronimo CMP, Farias MEL, Val FFA, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): a randomized, double-blind, phase Ib, placebo-controlled trial. Clin Infect Dis 2021; 72:e373–e381.

73. Veiga VC, Prats J, Farias DLC, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ 2021; 372:n84.

74. Lescure FX, Honda H, Fowler RA, et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 2021; 9:522–532.

75. Son AS, Kumar K, Choudhary NS, et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir Med 2021; 9:511–521.

76. Balkhair A, Al-Zakwani I, Al Busaidi M, et al. Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study. Int J Infect Dis 2021; 103:288–296.